Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 18/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 18/20 | 0.50 |
| ▸ | MTOR | P42345 | 16/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19760599 | 0.94 | PIK3C2B (0.52) | PIK3C2BPIK3CDMTORPIK3CGPIK3CB | |
| SCHEMBL17856476 | 0.93 | PIK3CD (0.60) | PIK3C2BPIK3CDMTORPIK3CGPIK3CB | |
| SCHEMBL17857143 | 0.89 | PIK3CD (0.44) | PIK3C2BPIK3CDMTORPIK3CGPIK3CB | |
| SCHEMBL17857290 | 0.86 | PIK3CD (0.66) | PIK3C2BPIK3CDMTORPIK3CGPIK3CB | |
| SCHEMBL17857149 | 0.86 | PIK3CD (0.45) | PIK3C2BPIK3CDMTORPIK3CGPIK3CB | |
| SCHEMBL19760604 | 0.85 | PIK3CD (0.45) | PIK3C2BPIK3CDMTORPIK3CGPIK3CB | |
| SCHEMBL19760540 | 0.84 | PIK3C2B (0.64) | PIK3C2BPIK3CDMTORPIK3CGPIK3CB | |
| SCHEMBL17857289 | 0.80 | PIK3CD (0.54) | PIK3C2BPIK3CDMTORPIK3CGPIK3CB | |
| SCHEMBL17857073 | 0.79 | PIK3CD (0.79) | PIK3C2BPIK3CDMTORPIK3CGPIK3CB | |
| SCHEMBL19913028 | 0.78 | PIK3C2B (0.66) | PIK3C2BPIK3CDMTORPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016097347-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | WO | disclosed |